These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 24979780)

  • 1. Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo.
    Lohr KM; Bernstein AI; Stout KA; Dunn AR; Lazo CR; Alter SP; Wang M; Li Y; Fan X; Hess EJ; Yi H; Vecchio LM; Goldstein DS; Guillot TS; Salahpour A; Miller GW
    Proc Natl Acad Sci U S A; 2014 Jul; 111(27):9977-82. PubMed ID: 24979780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals.
    Lohr KM; Chen M; Hoffman CA; McDaniel MJ; Stout KA; Dunn AR; Wang M; Bernstein AI; Miller GW
    Toxicol Sci; 2016 Sep; 153(1):79-88. PubMed ID: 27287315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.
    Taylor TN; Alter SP; Wang M; Goldstein DS; Miller GW
    Neuropharmacology; 2014 Jan; 76 Pt A(0 0):97-105. PubMed ID: 24025942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.
    Jourdain S; Morissette M; Morin N; Di Paolo T
    J Neuroendocrinol; 2005 Aug; 17(8):509-17. PubMed ID: 16011487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
    Sconce MD; Churchill MJ; Greene RE; Meshul CK
    Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity.
    Lohr KM; Stout KA; Dunn AR; Wang M; Salahpour A; Guillot TS; Miller GW
    ACS Chem Neurosci; 2015 May; 6(5):790-9. PubMed ID: 25746685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
    Kilbourn MR; Kuszpit K; Sherman P
    Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons.
    German DC; Liang CL; Manaye KF; Lane K; Sonsalla PK
    Neuroscience; 2000; 101(4):1063-9. PubMed ID: 11113355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice.
    Gainetdinov RR; Fumagalli F; Wang YM; Jones SR; Levey AI; Miller GW; Caron MG
    J Neurochem; 1998 May; 70(5):1973-8. PubMed ID: 9572281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ginkgo biloba extract (EGb 761) modulates the expression of dopamine-related genes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Rojas P; Ruiz-Sánchez E; Rojas C; Ogren SO
    Neuroscience; 2012 Oct; 223():246-57. PubMed ID: 22885234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration.
    Alter SP; Stout KA; Lohr KM; Taylor TN; Shepherd KR; Wang M; Guillot TS; Miller GW
    Exp Neurol; 2016 Jan; 275 Pt 1(Pt 1):17-24. PubMed ID: 26428905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism.
    Faherty CJ; Raviie Shepherd K; Herasimtschuk A; Smeyne RJ
    Brain Res Mol Brain Res; 2005 Mar; 134(1):170-9. PubMed ID: 15790541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine.
    Mingazov ER; Khakimova GR; Kozina EA; Medvedev AE; Buneeva OA; Bazyan AS; Ugrumov MV
    Mol Neurobiol; 2018 Apr; 55(4):2991-3006. PubMed ID: 28456940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems.
    Hall FS; Itokawa K; Schmitt A; Moessner R; Sora I; Lesch KP; Uhl GR
    Neuropharmacology; 2014 Jan; 76 Pt A(0 0):146-55. PubMed ID: 23978383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vesicular monoamine transporter 2 mediates fear behavior in mice.
    Branco RC; Burkett JP; Black CA; Winokur E; Ellsworth W; Dhamsania RK; Lohr KM; Schroeder JP; Weinshenker D; Jovanovic T; Miller GW
    Genes Brain Behav; 2020 Jun; 19(5):e12634. PubMed ID: 31898856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptors and gonadal steroids in vulnerability and protection of dopamine neurons in a mouse model of Parkinson's disease.
    Al-Sweidi S; Morissette M; Bourque M; Di Paolo T
    Neuropharmacology; 2011 Sep; 61(4):583-91. PubMed ID: 21586296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions of 1-methyl-4-phenylpyridinium and other compounds with P-glycoprotein: relevance to toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Staal RG; Yang JM; Hait WN; Sonsalla PK
    Brain Res; 2001 Aug; 910(1-2):116-25. PubMed ID: 11489261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    Hayley S; Crocker SJ; Smith PD; Shree T; Jackson-Lewis V; Przedborski S; Mount M; Slack R; Anisman H; Park DS
    J Neurosci; 2004 Feb; 24(8):2045-53. PubMed ID: 14985447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.
    Blesa J; Pifl C; Sánchez-González MA; Juri C; García-Cabezas MA; Adánez R; Iglesias E; Collantes M; Peñuelas I; Sánchez-Hernández JJ; Rodríguez-Oroz MC; Avendaño C; Hornykiewicz O; Cavada C; Obeso JA
    Neurobiol Dis; 2012 Oct; 48(1):79-91. PubMed ID: 22677034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.